Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04389710 · ClinicalTrials.gov registry record · Phase 2
Convalescent Plasma for the Treatment of COVID-19
A Phase 2 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT04389710 is a Phase 2 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 52 participants.
The verdict
NCT04389710, a Phase 2 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This protocol provides access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease. Following provision of informed consent, patients will be transfused with 1-2 units of ABO compatible convalescent plasma obtained from an individual who has recovered from documented infection with SARS-CoV-2 (as detailed in separate protocol). Safety information collected will include serious adverse events judged to be related to administration of convalescent plasma. Other information to be collected will include patient demographics, acute care facility resource utilization (total length of stay, days in ICU, days intubated), and survival to discharge from acute care facility.
Interventions
- DRUG Convalescent Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2020-04-15 |
| Est. Completion | 2020-12-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04389710
The ClinicalTrials.gov registry entry for NCT04389710 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Convalescent Plasma is the first listed.
NCT04389710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04389710 about?
NCT04389710 is a clinical study titled "Convalescent Plasma for the Treatment of COVID-19". This protocol provides access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease. Follow...
What is the current status of trial NCT04389710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2020-04-15. Estimated completion is 2020-12-07.
What interventions are being tested in trial NCT04389710?
The interventions under investigation include: Convalescent Plasma (DRUG).
Who is sponsoring clinical trial NCT04389710?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.